Literature DB >> 11443610

Reduced C-terminal Src kinase activity is correlated inversely with pp60(c-src) activity in colorectal carcinoma.

W R Cam1, T Masaki, Y Shiratori, N Kato, T Ikenoue, M Okamoto, K Igarashi, T Sano, M Omata.   

Abstract

BACKGROUND: Specific kinase activity of the proto-oncogene product pp60(c-src) is reported to be elevated in patients with carcinoma of the colon, and a novel cytoplasmic protein-tyrosine kinase, C-terminal Src kinase (Csk), has been found to inactivate the members of the Src family protein-tyrosine kinase. In this study, Csk activity and pp60(c-src) activity were examined in colorectal tumors as well as in colon carcinoma cell lines.
METHODS: Colorectal carcinoma tissue and adjacent nonneoplastic tissue from 24 patients, from 8 colon carcinoma cell lines, and from 1 normal colon cell line were used. The levels of pp60(c-src) and Csk in colorectal tissue and cell lines were analyzed by Western and/or Northern blot analysis, and their kinase activity levels were measured by in-gel kinase assay.
RESULTS: In the samples from 24 patients with colorectal carcinoma, pp60(c-src) kinase activity and protein levels were increased by 7.8 +/- 0.55 and 2.6 +/- 0.13 times the control levels, respectively. Conversely, the Csk protein level and its kinase activity were reduced by 0.53 +/- 0.08 and 0.53 +/- 0.09 times the control levels, respectively. pp60(c-src) kinase activity was correlated inversely with Csk activity (correlation coefficient = -0.71; P < 0.0001). Of the cell lines, pp60(c-src) kinase activity and protein levels, respectively, were 7.4 +/- 1.22 and 1.86 +/- 0.28 times greater than normal control levels. Csk protein level and kinase activity, respectively, were 0.54 +/- 0.13 and 0.52 +/- 0.11 times less normal control levels and were correlated with mRNA amount.
CONCLUSIONS: Csk mRNA, protein, and its kinase activity were reduced in colorectal carcinoma and were correlated with pp60(c-src) kinase activity level. The reduced activity of Csk may be involved in the transformation of a subset of colorectal carcinoma. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11443610     DOI: 10.1002/1097-0142(20010701)92:1<61::aid-cncr1292>3.0.co;2-d

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

1.  c-src activating mutation analysis in Chinese patients with colorectal cancer.

Authors:  Ye-Xiong Tan; Han-Tao Wang; Peng Zhang; Zhong-Hua Yan; Guan-Long Dai; Meng-Chao Wu; Hong-Yang Wang
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

2.  Fragmentation of phosphopeptides by atmospheric pressure MALDI and ESI/Ion trap mass spectrometry.

Authors:  Susanne C Moyer; Robert J Cotter; Amina S Woods
Journal:  J Am Soc Mass Spectrom       Date:  2002-03       Impact factor: 3.109

Review 3.  The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy.

Authors:  Christopher Lieu; Scott Kopetz
Journal:  Clin Colorectal Cancer       Date:  2010-04       Impact factor: 4.481

4.  Chemopreventive activity of plant flavonoid isorhamnetin in colorectal cancer is mediated by oncogenic Src and β-catenin.

Authors:  Shakir M Saud; Matthew R Young; Yava L Jones-Hall; Lilia Ileva; Moses O Evbuomwan; Jennifer Wise; Nancy H Colburn; Young S Kim; Gerd Bobe
Journal:  Cancer Res       Date:  2013-07-01       Impact factor: 12.701

5.  COOH-terminal Src kinase-mediated c-Jun phosphorylation promotes c-Jun degradation and inhibits cell transformation.

Authors:  Feng Zhu; Bu Young Choi; Wei-Ya Ma; Zhongliang Zhao; Yiguo Zhang; Yong Yeon Cho; Hong Seok Choi; Akira Imamoto; Ann M Bode; Zigang Dong
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

6.  Drosophila C-terminal Src kinase negatively regulates organ growth and cell proliferation through inhibition of the Src, Jun N-terminal kinase, and STAT pathways.

Authors:  Renee D Read; Erika A Bach; Ross L Cagan
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

7.  Srcasm inhibits Fyn-induced cutaneous carcinogenesis with modulation of Notch1 and p53.

Authors:  Liang Zhao; Weijie Li; Christine Marshall; Thomas Griffin; Matthew Hanson; Ryan Hick; Tzvete Dentchev; Erik Williams; Adrienne Werth; Christopher Miller; Hasan Bashir; Warren Pear; John T Seykora
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

Review 8.  Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer.

Authors:  Ann Marie Egloff; Jennifer R Grandis
Journal:  Semin Oncol       Date:  2008-06       Impact factor: 4.929

9.  Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer.

Authors:  Audrey Sirvent; Christine Benistant; Serge Roche
Journal:  Am J Cancer Res       Date:  2012-06-28       Impact factor: 6.166

10.  Antiproliferative effect of sulindac in colonic neoplasia prevention: role of COOH-terminal Src kinase.

Authors:  Dhananjay P Kunte; Ramesh K Wali; Jennifer L Koetsier; Hemant K Roy
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.